Fill out the form below to watch the webinar.
As you are establishing your commercial strategy for cell and gene therapy manufacturing, evaluating whether to build in-house capabilities or leverage a CDMO comes to the forefront of the discussion. When it comes to making the decision, a wide range of factors must be taken into account, from current investment capability to meeting your company’s long-term goals while maintaining flexibility in a continuously changing climate.
Watch this webinar, Build vs. Buy Dilemma – Economics of Manufacturing Cell-based Therapies, where our Thermo Fisher Scientific expert will take you through everything you need to consider when setting up a commercial strategy for success.
You’ll learn about:
- Key considerations related to the build vs. buy decision for cell therapy manufacturing
- Flexible and sustainable design strategies and best practices
- Contingency planning based on current market conditions and exit strategies